Tracon Pharmaceuticals Stock Price To Earning
TRACON Pharmaceuticals fundamentals help investors to digest information that contributes to TRACON Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of TRACON OTC Stock. The fundamental analysis module provides a way to measure TRACON Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TRACON Pharmaceuticals otc stock.
TRACON |
TRACON Pharmaceuticals OTC Stock Price To Earning Analysis
TRACON Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current TRACON Pharmaceuticals Price To Earning | (1.51) X |
Most of TRACON Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TRACON Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, TRACON Pharmaceuticals has a Price To Earning of -1.51 times. This is 105.84% lower than that of the Biotechnology sector and 130.63% lower than that of the Health Care industry. The price to earning for all United States stocks is 105.26% higher than that of the company.
TRACON Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TRACON Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of TRACON Pharmaceuticals could also be used in its relative valuation, which is a method of valuing TRACON Pharmaceuticals by comparing valuation metrics of similar companies.TRACON Pharmaceuticals is currently under evaluation in price to earning category among its peers.
TRACON Fundamentals
| Return On Equity | -12.77 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | (32.12) % | ||||
| Current Valuation | (2.64 M) | ||||
| Shares Outstanding | 2.68 M | ||||
| Shares Owned By Insiders | 2.20 % | ||||
| Shares Owned By Institutions | 11.42 % | ||||
| Number Of Shares Shorted | 166.13 K | ||||
| Price To Earning | (1.51) X | ||||
| Price To Book | 11.83 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 12.04 M | ||||
| Gross Profit | (13.89 M) | ||||
| EBITDA | (6.88 M) | ||||
| Net Income | (3.59 M) | ||||
| Cash And Equivalents | 13.58 M | ||||
| Cash Per Share | 0.63 X | ||||
| Total Debt | 968 K | ||||
| Debt To Equity | 0.35 % | ||||
| Current Ratio | 1.17 X | ||||
| Book Value Per Share | (0.66) X | ||||
| Cash Flow From Operations | 3.68 M | ||||
| Short Ratio | 0.95 X | ||||
| Earnings Per Share | 106.40 X | ||||
| Target Price | 30.5 | ||||
| Number Of Employees | 17 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 3.83 M | ||||
| Total Asset | 10.11 M | ||||
| Retained Earnings | (240.5 M) | ||||
| Working Capital | (1.09 M) | ||||
| Current Asset | 53.31 M | ||||
| Current Liabilities | 14.18 M | ||||
| Net Asset | 10.11 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in TRACON OTC Stock
If you are still planning to invest in TRACON Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TRACON Pharmaceuticals' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |